Pegcantratinib
Pegcantratinib (CT327) is a potent and selective TRKA antagonist with activity against TRKB and TRKC. Pegcantratinib can be used for research of CYLD cutaneous syndrome (CCS) and inflammatory dermatoses, such as psoriasis and concomitant pruritus[1].
Product Specifications
CAS Number
1233363-33-1
Product Name Alternative
CT327; SNA-120
UNSPSC
12352100
Target
Trk Receptor
Related Pathways
Neuronal Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer; Inflammation/Immunology
Smiles
O=C(N(CCOCCCOCC)C(O1)=O)[C@@]21[C@](C)(O3)N(C4=CC=CC=C45)C6=C5C7=C(C(NC7)=O)C8=C6N([C@H]3C2)C9=CC=CC=C98.[n]
Molecular Formula
(C2H4O) nC30H24N4O6
References & Citations
[1]Danilenko M, et al. Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial. JAMA Dermatol. 2018 Aug 1;154 (8) :913-921.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
TrkA
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
